The p53-mediated sensitivity of cancer cells to chemotherapeutic agents is conditioned by the status of the retinoblastoma protein

Journal of Pathology

Volumn 219, Issue 3, 2009, Pages 373-382

  Derenzini, Massimo ^a   Brighenti, Elisa ^a   Donati, Giulio ^a   Vici, Manuela ^a   Ceccarelli, Claudio ^a   Santini, Donatella ^a   Taffurelli, Mario ^a   Montanaro, Lorenzo ^a   Treré, Davide ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Breast cancer prognosis; Cancer cells; Chemotherapy; Immunohistochemistry; p53; Retinoblastoma protein; RT PCR; Western blot

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; METHOTREXATE; PROTEIN P53; RETINOBLASTOMA PROTEIN;

ARTICLE; BREAST CANCER; CANCER CELL; CHEMOSENSITIVITY; CONTROLLED STUDY; DISEASE FREE SURVIVAL; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UNIVARIATE ANALYSIS; WESTERN BLOTTING;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; EPIDEMIOLOGIC METHODS; FEMALE; GENE SILENCING; HUMANS; PROGNOSIS; RETINOBLASTOMA PROTEIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 70350440143     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.2612     Document Type: Article

References (40)

1. Harris SL, Levine AJ. The p53 pathway: positive and negative feedback loops. Oncogene 2005;24:2899-2908.
2. Vousden KH, Lu X. Live or let die: the cell's response to p53. Nat Rev Cancer 2002;2:594-604. (Pubitemid 37328926)
3. Johnstone RW, Ruefli AA, Lowe SW. Apoptosis: a link between cancer genetics and chemotherapy. Cell 2002;108:153-164.
4. Hall PA, McCluggage WG. Assessing p53 in clinical contexts: unlearned lessons and new perspectives. J Pathol 2006;208:1-6.
5. Sherr CJ, Roberts JM. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 1999;13:1501-1512.
6. David-Pfeuty T. The flexible evolutionary anchorage-dependent Pardee's restriction point of mammalian cells. How its deregulation may lead to cancer. Biochim Biophys Acta 2006;1765:38-66. (Pubitemid 41752940)
7. Sherr CJ, McCormick F. The RB and p53 pathways in cancer. Cancer Cell 2002;2:103-112.
8. Knudsen ES, Knudsen KE. Tailoring to RB. tumour suppressor status and therapeutic response. Nat Rev Cancer 2008;9:714-724.
9. Ellis IO, Bartlett J, Dowsett M, Humphreys S, Jasani B, Miller K, et al. Best Practice No. 176: updated recommendations for HER2 testing in the UK. J Clin Pathol 2004;57:233-237.
10. Shaulian E, Haviv I, Shaul Y, Oren M. Transcriptional repression by the C-terminal domain of p53. Oncogene 1995;10:671-680.
11. Morgenstern JP, Land H. Advanced mammalian gene transfer: high titre retroviral vectors with multiple drug selection markers and a complementary helper-free packaging cell line. Nucleic Acids Res 1990;18:3587-3596. (Pubitemid 20191808)
12. Lau WM, Ho TH, Hui KM. p16(INK4a)-silencing augments DNA damage-induced apoptosis in cervical cancer cells. Oncogene 2007;26:6050-6060.
13. Derenzini M, Donati G, Mazzini G, Montanaro L, Vici M, Ceccarelli C, et al. Loss of retinoblastoma tumor suppressor protein makes human breast cancer cells more sensitive to antimetabolite exposure. Clin Cancer Res 2008;14:2199-2209. (Pubitemid 351551133)
14. Carnero A, Hudson JD, Price CM, Beach DH. p16(INK4a) and p19ARF act in overlapping pathways in cellular immortalization. Nat Cell Biol 2000;2:148-155. (Pubitemid 30781129)
15. Esrig D, Spruck CH III, Nichols PW, Chaiwun B, Steven K, Groshen S, et al. p53 nuclear protein accumulation correlates with mutations in the p53 gene, tumor grade, and stage in bladder cancer. Am J Pathol 1993;43:1389-1397. (Pubitemid 24057109)
16. Nenutil R, Smardova J, Pavlova S, Hanzelkova Z, Muller P, Fabian P, et al. Discriminating functional and non-functional p53 in human tumours by p53 and MDM2 immunohistochemistry. J Pathol 2005;207:251-259. (Pubitemid 41556448)
17. Derenzini M, Ceccarelli C, Santini D, Taffurelli M, Trere D. The prognostic value of the AgNOR parameter in human breast cancer depends on the RB and p53 status. J Clin Pathol 2004;57:755-761. (Pubitemid 38901493)
18. Musgrove EA, Lilischkis R, Cornish AL, Lee CS, Setlur V, Seshadri R, et al. Expression of the cyclin-dependent kinase inhibitors p16INK4, p15INK4B and p21WAF1/CIP1 in human breast cancer. Int J Cancer 1995;63:584-591.
19. Myöhänen SK, Baylin SB, Herman JG. Hypermethylation can selectively silence individual p16(INK4a) alleles in neoplasia. Cancer Res 1998;58:591-593.
20. Barnes DM, Dublin EA, Fisher CJ, Levison DA, Millis RR. Immunohistochemical detection of p53 protein in mammary carcinoma: an important new independent indicator of prognosis. Human Pathol 1993;24:469-476.
21. Silvestrini R, Benini E, Daidone MG, Veneroni S, Boracchi P, Cappelletti V, et al. p53 as an independent prognostic marker in lymph node-negative breast cancer patients. J Natl Cancer Inst 1993;85:965-970. (Pubitemid 23177582)
22. MacGrogan G, Bonichon F, de Mascarel I, Trojani M, Durand M, Avril A, et al. Prognostic value of p53 in breast invasive ductal carcinoma: an immunohistochemical study on 942 cases. Breast Cancer Res Treat 1995;36:71-81.
23. Silvestrini R, Daidone MG, Benini E, Faranda A, Tomasic G, Boracchi P, et al. Validation of p53 accumulation as a predictor of distant metastasis at 10 years of follow-up in 1400 node-negative breast cancers. Clin Cancer Res 1996;2:2007-2013. (Pubitemid 27006633)
24. Thor AD, Berry DA, Budman DR, Muss HB, Kute T, Henderson IC, et al. ErbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer. J Natl Cancer Inst 1998;90:1346-1360. (Pubitemid 28439959)
25. Chappuis PO, Estreicher A, Dieterich B, Bonnefoi H, Otter M, Sappino AP, et al. Prognostic significance of p53 mutation in breast cancer: frequent detection of non-missense mutations by yeast functional assay. Int J Cancer 1999;84:587-593.
26. Elledge RM, Gray R, Mansour E, Yu Y, Clark GM, Ravdin P, et al. Accumulation of p53 protein as a possible predictor of response to adjuvant combination chemotherapy with cyclophosphamide, methotrexate, fluorouracil, and prednisone for breast cancer. J Natl Cancer Inst 1995;87:1254-1256.
27. Sjögren S, Inganäs M, Norberg T, Lindgren A, Nordgren H, Holmberg L, et al. The p53 gene in breast cancer: prognostic value of complementary DNA sequencing versus immunohistochemistry. J Natl Cancer Inst 1996;88:173-182. (Pubitemid 26065829)
28. Clahsen PC, van de Velde CJ, Duval C, Pallud C, Mandard AM, Delobelle-Deroide A, et al. p53 protein accumulation and response to adjuvant chemotherapy in premenopausal women with node-negative early breast cancer. J Clin Oncol 1998;16:470-479. (Pubitemid 28135588)
29. Broët P, Spyratos F, Romain S, Quillien V, Daver A, Ricolleau G, et al. Prognostic value of uPA and p53 accumulation measured by quantitative biochemical assays in 1245 primary breast cancer patients: a multicentre study. Br J Cancer 1999;80:536-545. (Pubitemid 29213211)
30. Penault-Llorca F, Cayre A, Bouchet Mishellany F, Amat S, Feillel V, Le Bouedec G, et al. Induction chemotherapy for breast carcinoma: predictive markers and relation with outcome. Int J Oncol 2003;22:1319-1325.
31. Aas T, Børresen AL, Geisler S, Smith-Sørensen B, Johnsen H, Varhaug JE, et al. Specific p53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nat Med 1996;2:811-814. (Pubitemid 26225099)
32. Miller LD, Smeds J, George J, Vega VB, Vergara L, Ploner A, et al. An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc Natl Acad Sci USA 2005;102:13550-13555. (Pubitemid 41420886)
33. Olivier M, Langerød A, Carrieri P, Bergh J, Klaar S, Eyfjord J, et al. The clinical value of somatic TP53 gene mutations in 1794 patients with breast cancer. Clin Cancer Res 2006;12:1157-1167. (Pubitemid 43342504)
34. Sotiriou C, Neo SY, McShane LM, Korn EL, Long PM, Jazaeri A, et al. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci USA 2003;100:10393-10398. (Pubitemid 37071889)
35. Bertheau P, Turpin E, Rickman DS, Espié M, de Reyniès A, Feugeas JP, et al. Exquisite sensitivity of TP53 mutant and basal breast cancers to a dose-dense epirubicin-cyclophosphamide regimen. PLoS Med 2007;4:585-594. (Pubitemid 46495326)
36. Bidard FC, Matthieu MC, Chollet P, Raoefils I, Abrial C, Dômont J, et al. p53 status and efficacy of primary anthracyclines/alkylating agent-based regimen according to breast cancer molecular classes. Ann Oncol 2008;19:1261-1265. (Pubitemid 351916575)
37. Treré D, Brighenti E, Donati G, Ceccarelli C, Santini S, Taffurelli M, et al. High prevalence of retinoblastoma protein loss in triple-negative breast cancers and its association with a good prognosis in patients treated with adjuvant chemotherapy. Ann Oncol 2009;DOI:10.1093/annonc/ mdp209.
38. Soussi T, Béroud C. Assessing TP53 status in human tumours to evaluate clinical outcome. Nat Rev Cancer 2001;1:233-240. (Pubitemid 33741898)
39. Burke L, Flieder DB, Guinee DG, Brambilla E, Freedman AN, Bennett WP, et al. Prognostic implications of molecular and immunohistochemical profiles of the Rb and p53 cell cycle regulatory pathways in primary non-small cell lung carcinoma. Clin Cancer Res 2005;11:232-241. (Pubitemid 40075800)
40. Voorhoeve PM, Agami R. The tumor-suppressive functions of the human INK4A locus. Cancer Cell 2003;4:311-319. (Pubitemid 37329795)